GRCE Financials

Income Statement
MetricQ1 2027Q4 2026Q3 2026Q2 2026Q1 2026
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
15.9M
+428.8%
3.0M
+22.9%
2.4M
-3.2%
2.5M
-18.2%
3.1M
R&D
697.0K
+66.0%
420.0K
-9.1%
462.0K
-18.7%
568.0K
-40.5%
955.0K
SG&A
1.7M
-34.9%
2.6M
+30.3%
2.0M
+1.3%
2.0M
-8.1%
2.1M
Operating Income
-15917000
-428.8%
-3010000
-22.9%
-2449000
+3.2%
-2529000
+18.2%
-3090000
EBITDA
-2382000
+20.8%
-3008000
-23.0%
-2446000
+3.3%
-2529000
+18.1%
-3088000
Net Income
-15790000
-1240.4%
-1178000
+49.1%
-2315000
-146.8%
-938000
+72.1%
-3362000
EPS (Basic)
$-0.91
-1200.0%
$-0.07
+50.0%
$-0.14
-133.3%
$-0.06
+71.4%
$-0.21
EPS (Diluted)
$-0.91
-1200.0%
$-0.07
+50.0%
$-0.14
-133.3%
$-0.06
+71.4%
$-0.21
Shares (Diluted)
17.3M
+0.1%
17.3M
+1.9%
16.9M
+6.3%
15.9M
+0.0%
15.9M
Grace Therapeutics (GRCE) โ€” Financials